ACTRN12622000390785招募中未知
Project Twenty21 Australia: A Prospective, Real-World Observational Cohort Study to Investigate the Efficacy of Medicinal Cannabis
Releaf Training and Education trading as the Australasian College of Cannabinoid Medicine0 个研究点目标入组 500 人开始时间: 2022年3月7日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •1. Patients, females and males, aged 18 years and over with a diagnosis which falls under one of the following four study categories: chronic pain, anxiety, PTSD, and multiple sclerosis and who are prescribed medicinal cannabis as per standard clinical practice by a clinician at Releaf Clinics.
- •2. In the professional opinion of the treating clinician, the patient is eligible to be prescribed medicinal cannabis in Australia.
- •3. Ability to fully understand the potential side effects associated with medicinal cannabis, and the fact that driving with any amount of THC in your system is an offence under Australian driving laws in all states and territories
- •4. Ability to fully understand the requirements of participation in the study.
- •5. Provide written informed consent to participate in the study and are willing to comply with the study procedures.
- •6. Agree to be prescribed medicinal cannabis products from the Project Formulary.
排除标准
- •1.Patients currently using recreational cannabis (where use is chronic and more than three days per week for the past 2 months) or medicinal cannabis for medical reasons
- •2.Evidence of clinically relevant haematological, gastrointestinal, hepatic, renal, endocrine, pulmonary, neurologic or psychiatric disorder which in the opinion of the medical practitioner should preclude them from participating in the study.
- •3.Known allergy to medicinal cannabis, CBD or any of the components of the medicinal cannabis products in the Project Formulary.
- •4.Pregnancy or active breast feeding.
- •5.Clinically significant abnormalities in baseline laboratory test results including liver function and kidney function: Creatinine > 1.5 times upper limit of normal; ALT, AST or ALP > 2 times upper limit of normal.
- •6.Taking warfarin or any other blood thinning medication (which may interact adversely with CBD).
- •7.Have participated in a clinical trial or receipt of an experimental therapy within 30 days prior to inclusion.
- •8.Unwilling or unable to provide written informed consent.
研究者
相似试验
招募中
不适用
The Australian and New Zealand Collaborative Perfusion Registry: The establishment and maintenance of a prospective data set on Cardiac Surgical Procedures performed in centres throughout Australia and New Zealand to foster and grow high quality research in the perfusion sciences.Cardiac SurgeryCardiovascular - Other cardiovascular diseasesSurgery - Other surgeryACTRN12614000832673Flinders Medical Centre100,000
已完成
不适用
The Sources of Strength Australia Project: a trial investigating the effect of the Sources of Strength program on help-seeking for suicidality in adolescents.Help-seekingSuicidalityHelp-seekingSuicidalityMental Health - SuicideACTRN12616000048482The National Institute for Mental Health Research, The Australian National University1,781
已完成
1 期
Australian Integrated Mental Health InitiativeACTRN12605000531617Professor David Kavanagh (& Rural Stream)1,000
招募中
不适用
Australian Epilepsy ProjectEpilepsyACTRN12623000008628Florey Institute of Neuroscience and Mental Health4,000
已完成
不适用
A feasibility study to determine whether Australian children aged 8-13 years will eat almonds for 8 weeks and the impact on cognitive perfomance.Cognitive PerformanceSleep hygieneDiet and Nutrition - Other diet and nutrition disordersMental Health - Studies of normal psychology, cognitive function and behaviourACTRN12618000887279niversity of South Australia40